Organization and Operations (Details) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Jun. 30, 2015 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($)
Minimum number of disease pathways within which multiple biological targets are modulated during treatment	1	1
Number of bioactives used to engineer bi-functional product candidates		2
Number of SMART linkers	1	1
Initial public offering
Proceeds from initial public offering, net of issuance costs | $		$ 62,763
Common Stock issued upon conversion of Preferred Stock		9,029,549
Number of shares after conversion of warrants	24,566	24,566
Accumulated deficit | $	$ (89,920)	$ (89,920)	$ (75,380)
Initial public offering
Initial public offering
Issuance of stock (in shares)	5,750,000
Share price (in dollars per share) | $ / shares	$ 12.00	$ 12.00
Proceeds from initial public offering, net of issuance costs | $	$ 61,800
Underwriting discounts, commissions and offering-related expenses payable | $	$ 7,200
Common Stock issued upon conversion of Preferred Stock	9,029,549
Initial public offering | Warrants for the purchase of Common Stock
Initial public offering
Number of shares after conversion of warrants	24,566	24,566
Over-Allotment option for underwriters
Initial public offering
Issuance of stock (in shares)	750,000
Preferred Stock | Initial public offering
Initial public offering
Preferred Stock warrants converted (in shares)	315,688